Immunological and clinical efficacy of low dose IL-2 was assessed in a recent open-label, phase I-IIa study of 46 patients with multiple autoimmune conditions: including rheumatoid arthritis, ankylosing spondylitis, SLE, psoriasis, Behcet's disease, granulomatosis with polyangiitis, Takayasu's disease, Crohn's disease, ulcerative colitis, AIH or PSC. The gene discussed is IL2; the disease is systemic lupus erythematosus.